{"id":"W4362522571","doi":"10.1038/s41591-023-02297-5","title":"Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Ignyta; Y-mAbs Therapeutics; Varian Medical Systems; St. Baldrick's Foundation; Pfizer; Actuate Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; Alex's Lemonade Stand Foundation for Childhood Cancer; V Foundation for Cancer Research","keywords":"Medicine; Internal medicine; Refractory (planetary science); Neuroblastoma; Chemotherapy; Cyclophosphamide; Adverse effect; Clinical trial; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001441696,0.001005058,0.001463633,0.0002486335,0.0002771695,0.0007355508,0.0005660825,0.0008721448,0.00242659],"category_scores_gemma":[0.0009308632,0.0002550383,0.0009336508,0.0002408589,0.0006130852,0.0006667036,0.0002562702,0.002026514,0.0003734142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007973091,"about_ca_system_score_gemma":0.0009681511,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008330175,"about_ca_topic_score_gemma":0.002673534,"domain_scores_codex":[0.9996062,0.0002247694,0.00002437329,0.00005398779,0.00003651934,0.0000542316],"domain_scores_gemma":[0.9995315,0.0001081886,0.0001124798,0.0000244729,0.00003150034,0.0001919557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7868476,0.02565572,0.007389355,0.002153538,0.00215756,0.0005771678,0.0003154418,0.004980044,0.03496205,0.0004650261,0.009550875,0.1249456],"study_design_scores_gemma":[0.664944,0.3080051,0.01294371,0.0001428889,0.0009638734,0.0007026111,0.00008013979,0.002433846,0.004726184,0.0002836261,0.00472301,0.00005104836],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897187,0.005241134,0.0003392679,0.0006082613,0.0001024228,0.001099092,0.001194897,0.00009138005,0.001604989],"genre_scores_gemma":[0.9874362,0.004271889,0.001138084,0.0006977516,0.0001425424,0.001335633,0.002625367,0.00002709931,0.002325392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00242659,"threshold_uncertainty_score":0.008117795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03487887887345568,"score_gpt":0.3942430159057496,"score_spread":0.3593641370322939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}